10x Genomics Wins Patent Verdict Against Qiagen Subsidiary with $4.8M Damages

Key Facts

1A jury in the U.S. District Court for the District of Delaware found that Parse Biosciences willfully infringed three patents licensed to 10x Genomics.

In a move that strengthens intellectual property protections within the biotechnology sector, 10x Genomics has secured a significant legal victory in the U.S. District Court for the District of Delaware. A jury found that Parse Biosciences, a subsidiary of Qiagen, willfully infringed three patents exclusively licensed to 10x Genomics. According to reports, the jury rejected invalidity challenges, reinforcing the competitive moat for the life science technology leader.

The verdict awarded 10x Genomics over $4.8 million in damages for sales of Parse's infringing Evercode products from February 2021 through June 30, 2026. The damages are calculated based on a 14% royalty rate on infringing sales. The litigation involved patents licensed to Scale Biosciences, which has been integrated into 10x Genomics since 2025, and the company now intends to seek enhanced damages and a permanent injunction against further infringement.

Based on market data, specific price levels for Qiagen (QGEN) or 10x Genomics are currently unavailable. Investors are focusing on the legal outcome's impact on long-term profitability and market share. On the macroeconomic front, U.S. Gross Domestic Product data released on August 26, 2026, showed a 1.5% growth rate, matching forecasts and providing a stable environment for high-growth tech sectors.